Wordt geladen...
Predicting Response to Vedolizumab in Inflammatory Bowel Disease
Vedolizumab is known to be safe, well-tolerated, and effective. However, as personalization becomes an increasingly important aspect of IBD care and in lieu of guidelines to inform clinicians on positioning of biologics, there is a need to reliably predict response to inform patient preferences and...
Bewaard in:
| Gepubliceerd in: | Front Med (Lausanne) |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7145386/ https://ncbi.nlm.nih.gov/pubmed/32300596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2020.00076 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|